Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Non Operating Income (2016 - 2025)

ProQR Therapeutics' Non Operating Income history spans 5 years, with the latest figure at $327335.4 for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 36.45% to $327335.4 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 22.81% decrease, with the full-year FY2021 number at -$3.3 million, down 263.61% from a year prior.
  • Non Operating Income hit $327335.4 in Q3 2025 for ProQR Therapeutics, up from $217336.3 in the prior quarter.
  • Over the last five years, Non Operating Income for PRQR hit a ceiling of $1.2 million in Q2 2022 and a floor of -$3.0 million in Q2 2021.
  • Historically, Non Operating Income has averaged $76578.6 across 5 years, with a median of $374292.8 in 2023.
  • Biggest five-year swings in Non Operating Income: tumbled 361.03% in 2022 and later skyrocketed 190.79% in 2024.
  • Tracing PRQR's Non Operating Income over 5 years: stood at -$340903.3 in 2021, then soared by 277.16% to $603956.3 in 2022, then crashed by 34.57% to $395158.3 in 2023, then soared by 30.34% to $515064.9 in 2024, then crashed by 36.45% to $327335.4 in 2025.
  • Business Quant data shows Non Operating Income for PRQR at $327335.4 in Q3 2025, $217336.3 in Q2 2025, and $478607.4 in Q1 2025.